esophageal adenocarcinoma; ion channels; therapy; venom; Molecular Medicine; Molecular Biology
Abstract :
[en] The incidence of esophageal adenocarcinoma is rising in Western countries. Despite advances in chemotherapy and immunotherapy, the prognosis remains poor, with an overall 5-year survival rate below 15%. A major challenge is the cancer's poor and often unpredictable response to current treatments. Animal venoms represent a promising yet underexplored source of therapeutic agents, offering millions of structurally diverse and highly potent bioactive peptides that can modulate a wide array of molecular targets. However, only a small fraction of these peptides has been pharmacologically characterized. This review presents the therapeutic potential of venom-derived peptides in cancer treatment, summarizes the role of ion channels in esophageal adenocarcinoma (EAC), and discusses peptides targeting ion channels that may offer new opportunities for future EAC treatment.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Freuville, Lou ; Université de Liège - ULiège > Molecular Systems (MolSys)
Matthys, Chloé; Laboratory of Molecular Cancer Biology, URPhyM, NARILIS, University of Namur, Namur 5000, Belgium
Gilliaux, Quentin; Department of Oncology, CHU-UCL Namur, site de Godinne, Yvoir 5530, Belgium
D'Hondt, Lionel; Department of Oncology, CHU-UCL Namur, site de Godinne, Yvoir 5530, Belgium
Gillet, Jean-Pierre ; Laboratory of Molecular Cancer Biology, URPhyM, NARILIS, University of Namur, Namur 5000, Belgium. Electronic address: jean-pierre.gillet@unamur.be
Language :
English
Title :
Could venom-derived therapeutics resolve treatment resistance in refractory EAC?
Sung, H. et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249
Uhlenhopp, D.J. et al. (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin. J. Gastroenterol. 13, 1010–1021
Freuville, L. et al. (2024) Venom-derived peptides for breaking through the glass ceiling of drug development. Front. Chem. 12, 1465459
Tasoulis, T. and Isbister, G.K. (2023) A current perspective on snake venom composition and constituent protein families. Arch. Toxicol. 97, 133–153
Xia, Z. et al. (2023) Scorpion venom peptides: molecular diversity, structural characteristics, and therapeutic use from channelopathies to viral infections and cancers. Pharmacol. Res. 197, 106978
Langenegger, N. et al. (2019) Spider venom: components, modes of action, and novel strategies in transcriptomic and proteomic analyses. Toxins 11, 611
Herzig, V. et al. (2020) Animal toxins—nature’s evolutionary-refined toolkit for basic research and drug discovery. Biochem. Pharmacol. 181, 114096
Abd El-Aziz, T.M. et al. (2020) Advances in venomics: modern separation techniques and mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1160, 122352
Honing, J. et al. (2025) Surveillance of Barrett’s esophagus patients in an expert center is associated with low disease-specific mortality. United Eur. Gastroenterol. J. 13, 220–228
Fatehi Hassanabad, A. et al. (2020) Esophageal carcinoma: towards targeted therapies. Cell. Oncol. 43, 195–209
Shah, M.A. et al. (2024) First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. J. Clin. Oncol. 42, 250–250
Brown, D.G. and Boström, J. (2016) Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone? Miniperspective. J. Med. Chem. 59, 4443–4458
Bordon, K.D.C.F. et al. (2020) From animal poisons and venoms to medicines: achievements, challenges and perspectives in drug discovery. Front. Pharmacol. 11, 1132
Fu, S. et al. (2017) First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest. New Drugs 35, 324–333
Khattar, V. et al. (2022) Calcium selective channel TRPV6: structure, function, and implications in health and disease. Gene 817, 146192
El-Qassas, J. et al. (2024) Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy. Bioresour. Bioprocess. 11, 93
Mabunda, I.G. et al. (2025) Scorpion venoms from the Buthidae family: a dual study of proteomic composition and anticancer potentials. Toxicon 266, 108542
Almeida, J.R. et al. (2025) Snake venom-derived peptides as anticancer candidates: pioneering next-generation therapies. Biochim. Biophys. Acta BBA – Rev. Cancer 1880, 189479
He, J. et al. (2013) Growth inhibitory effects and molecular mechanisms of crotoxin treatment in esophageal Eca-109 cells and transplanted tumors in nude mice. Acta Pharmacol. Sin. 34, 295–300
Muller, S.P. et al. (2018) Crotoxin from Crotalus durissus terrificus venom: in vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines. Toxicon 156, 13–22
Lv, J. et al. (2017) Arenobufagin activates p53 to trigger esophageal squamous cell carcinoma cell apoptosis in vitro and in vivo. Oncol. Targets Ther. 10, 1261–1267
Lin, S. et al. (2017) Bufadienolides induce p53-mediated apoptosis in esophageal squamous cell carcinoma cells in vitro and in vivo. Oncol. Lett. 15, 1566–1572
Zhu, H. et al. (2014) Melittin radiosensitizes esophageal squamous cell carcinoma with induction of apoptosis in vitro and in vivo. Tumor. Biol. 35, 8699–8705
Zhou, C. et al. (2020) TERT promoter regulating melittin expression induces apoptosis and G0/G1 cell cycle arrest in esophageal carcinoma cells. Oncol. Lett. 21, 16
Huang, J-Y. et al. (2021) Melittin suppresses epithelial–mesenchymal transition and metastasis in human gastric cancer AGS cells via regulating Wnt/BMP associated pathway. Biosci. Biotechnol. Biochem. 85, 2250–2262
Shi, P. et al. (2022) Pharmacological effects and mechanisms of bee venom and its main components: recent progress and perspective. Front. Pharmacol. 13, 1001553
Taura, J. et al. (2021) Comparison of K+ channel families. In Pharmacology of Potassium Channels (Vol. 267) (Gamper, N. and Wang, K., eds), pp. 1–49, Springer International Publishing
Zúñiga, L. et al. (2022) Potassium channels as a target for cancer therapy: current perspectives. Oncol. Targets Ther. 15, 783–797
Kim, H.J. et al. (2022) Chloride channels and transporters: roles beyond classical cellular homeostatic pH or ion balance in cancers. Cancers 14, 856
Tajada, S. and Villalobos, C. (2020) Calcium permeable channels in cancer hallmarks. Front. Pharmacol. 11, 968
Liu, H. et al. (2024) Voltage-gated sodium channels in cancers. Biomark. Res. 12, 70
Gründer, S. et al. (2024) Acid-sensing ion channels and downstream signalling in cancer cells: is there a mechanistic link? Pflüg. Arch. – Eur. J. Physiol. 476, 659–672
Marini, M. et al. (2023) TRP channels in cancer: signaling mechanisms and translational approaches. Biomolecules 13, 1557
Bell, D.C. et al. (2023) News and views on ion channels in cancer: is cancer a channelopathy? Front. Pharmacol. 14, 1258933
Zhang, G. et al. (2018) Combined targeted ion channel therapy: can it be an alternative choice for esophageal cancer patients? Med. Hypotheses 117, 59–62
Zhou, S. et al. (2025) Targeting ion channels for cancer therapy: from pathophysiological mechanisms to clinical translation. Pharmaceuticals 18, 1521
Arcangeli, A. et al. (2023) The role of potassium channels in tumours of the gastrointestinal tract: a focus on the human ether-à-go-go related gene 1 channels. J. Physiol. 601, 1597–1610
Shorthouse, D. et al. (2023) KCNQ potassium channels modulate Wnt activity in gastro-oesophageal adenocarcinomas. Life Sci. Alliance 6, e202302124
Foley, K. et al. (2024) SMAD4 and KCNQ3 alterations are associated with lymph node metastases in oesophageal adenocarcinoma. Biochim. Biophys. Acta BBA – Mol. Basis Dis. 1870, 166867
He, S. et al. (2020) HERG channel and cancer: a mechanistic review of carcinogenic processes and therapeutic potential. Biochim. Biophys. Acta BBA – Rev. Cancer 1873, 188355
Iorio, J. et al. (2022) Prognostic role of hERG1 potassium channels in neuroendocrine tumours of the ileum and pancreas. Int. J. Mol. Sci. 23, 10623
Lastraioli, E. et al. (2016) hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett’s esophagus and can be exploited for a novel endoscopic surveillance. Oncotarget 7, 59535–59547
Luo, L. et al. (2018) Centipedes subdue giant prey by blocking KCNQ channels. Proc. Natl. Acad. Sci. U S A 115, 1646–1651
Titaux-Delgado, G. et al. (2023) Beta-KTx14.3, a scorpion toxin, blocks the human potassium channel KCNQ1. Biochim. Biophys. Acta BBA – Proteins Proteomics 1871, 140906
Chen, J. et al. (2015) SjAPI-2 is the first member of a new neurotoxin family with Ascaris-type fold and KCNQ1 inhibitory activity. Int. J. Biol. Macromol. 79, 504–510
Matsumura, K. et al. (2021) Mechanism of hERG inhibition by gating-modifier toxin, APETx1, deduced by functional characterization. BMC Mol. Cell Biol. 22, 3
Beltrán-Vidal, J. et al. (2021) Colombian scorpion Centruroides margaritatus: purification and characterization of a gamma potassium toxin with full-block activity on the hERG1 channel. Toxins 13, 407
Pinheiro-Junior, E.L. et al. (2022) A tale of toxin promiscuity: the versatile pharmacological effects of Hcr 1b-2 sea anemone peptide on voltage-gated ion channels. Mar. Drugs 20, 147
Martínez-Hernández, L. et al. (2023) κO-SrVIA conopeptide, a novel inhibitor peptide for two members of the human EAG potassium channel family. Int. J. Mol. Sci. 24, 11513
Verkest, C. et al. (2022) Mechanisms of action of the peptide toxins targeting human and rodent acid-sensing ion channels and relevance to their in vivo analgesic effects. Toxins 14, 709
Peigneur, S. et al. (2012) A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins. FASEB J. 26, 5141–5151
Bychkov, M. et al. (2020) Mambalgin-2 induces cell cycle arrest and apoptosis in glioma cells via interaction with ASIC1a. Cancers 12, 1837
Cristofori-Armstrong, B. et al. (2019) The modulation of acid-sensing ion channel 1 by PcTx1 is pH-, subtype- and species-dependent: importance of interactions at the channel subunit interface and potential for engineering selective analogues. Biochem. Pharmacol. 163, 381–390
Duggan, N.M. et al. (2021) Total synthesis of the spider-venom peptide Hi1a. Org. Lett. 23, 8375–8379
Salinas, M. et al. (2021) Mambalgin-1 pain-relieving peptide locks the hinge between α4 and α5 helices to inhibit rat acid-sensing ion channel 1a. Neuropharmacology 185, 108453
Redd, M.A. et al. (2021) Therapeutic inhibition of acid-sensing ion channel 1a recovers heart function after ischemia–reperfusion injury. Circulation 144, 947–960
Bychkov, M.L. et al. (2021) Mambalgin-2 inhibits growth, migration, and invasion of metastatic melanoma cells by targeting the channels containing an ASIC1a subunit whose up-regulation correlates with poor survival prognosis. Biomedicines 9, 1324
Sudarikova, A.V. et al. (2022) Mambalgin-2 inhibits lung adenocarcinoma growth and migration by selective interaction with ASIC1/α-ENaC/γ-ENaC heterotrimer. Front. Oncol. 12, 904742
Cutliffe, A.L. et al. (2021) Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma. Explor. Target. Anti-Tumor Ther. 2, 543–575
Zhang, Q. et al. (2018) Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia. Channels 12, 201–218
Xu, E. et al. (2013) Genome-wide methylation analysis shows similar patterns in Barrett’s esophagus and esophageal adenocarcinoma. Carcinogenesis 34, 2750–2756
Xie, F. et al. (2022) Analysis of cancer-promoting genes related to chemotherapy resistance in esophageal squamous cell carcinoma. Ann. Transl. Med. 10, 92–92
Huang, Y. et al. (2026) Scorpion venom neurotoxins: molecular diversity, mechanisms, and drug scaffolds. Toxins 18, 25
de Waard, S. et al. (2020) Maurocalcin and its analog MCaE12A facilitate Ca2+ mobilization in cardiomyocytes. Biochem. J. 477, 3985–3999
Haji-Ghassemi, O. et al. (2023) Cryo-EM analysis of scorpion toxin binding to Ryanodine Receptors reveals subconductance that is abolished by PKA phosphorylation. Sci. Adv. 9, eadf4936
Oliveira-Mendes, B.B.R.D. et al. (2018) CPP-Ts: a new intracellular calcium channel modulator and a promising tool for drug delivery in cancer cells. Sci. Rep. 8, 14739
Tang, D. et al. (2026) Molecular diversity of peptides from Pandercetes sp. spider venom and antagonistic activity on voltage-gated calcium channels of the κ-LhTx-1 toxin. Int. J. Biol. Macromol. 337, 149490
Hanssens, L.S. et al. (2021) CFTR protein: not just a chloride channel? Cells 10, 2844
Bhattacharya, R. et al. (2022) CFTR and gastrointestinal cancers: an update. J. Pers. Med. 12, 868
Parisi, G.F. et al. (2023) Cystic fibrosis and cancer: unraveling the complex role of CFTR gene in cancer susceptibility. Cancers 15, 4244
Gharahkhani, P. et al. (2016) Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 17, 1363–1373
Boltman, T. et al. (2023) Diagnostic and therapeutic approaches for glioblastoma and neuroblastoma cancers using chlorotoxin nanoparticles. Cancers 15, 3388
Lopez-Charcas, O. et al. (2022) Voltage-gated sodium channel NaV1.5 controls NHE-1-dependent invasive properties in colon cancer cells. Cancers 15, 46
Sui, Q. et al. (2021) Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cancer Lett. 500, 119–131
Horne, J. et al. (2021) Sodium ion channels as potential therapeutic targets for cancer metastasis. Drug Discov. Today 26, 1136–1147
Cardoso, F.C. (2020) Multi-targeting sodium and calcium channels using venom peptides for the treatment of complex ion channels-related diseases. Biochem. Pharmacol. 181, 114107
Wu, T. et al. (2019) Spider venom peptides as potential drug candidates due to their anticancer and antinociceptive activities. J. Venom. Anim. Toxins Trop. Dis. 25, e146318
Shiozaki, A. et al. (2023) Cancer stem cells of esophageal adenocarcinoma are suppressed by inhibitors of TRPV2 and SLC12A2. Ann. Surg. Oncol. 30, 8743–8754
Becskeházi, E. et al. (2020) Oesophageal ion transport mechanisms and significance under pathological conditions. Front. Physiol. 11, 855
Boult, J. et al. (2008) Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin. Cancer. Res. 14, 379–387
Lee, J. and Roh, J-L. (2023) Promotion of ferroptosis in head and neck cancer with divalent metal transporter 1 inhibition or salinomycin. Hum. Cell 36, 1090–1098
Kaftan, G. et al. (2024) Heteronemin promotes iron-dependent cell death in pancreatic cancer. Naunyn Schmiedebergs Arch Pharmacol. 397, 1865–1874
Song, Q. et al. (2021) Temozolomide drives ferroptosis via a DMT1-dependent pathway in glioblastoma cells. Yonsei. Med. J. 62, 843
Fitzgerald, R.C. et al. (1998) Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett’s esophagus. Am. J. Physiol.-Gastrointest. Liver Physiol. 275, G47–G55
Park, S.Y. et al. (2015) Intrinsic resistance triggered under acid loading within normal esophageal epithelial cells: NHE1- and ROS-mediated survival. J. Cell Physiol. 230, 1503–1514
Korsós, M.M. et al. (2021) Mouse organoid culture is a suitable model to study esophageal ion transport mechanisms. Am. J. Physiol.-Cell Physiol. 321, C798–C811
Wang, L-L. et al. (2023) The promoting effects of Grin2d expression in tumorigenesis and the aggressiveness of esophageal cancer. Histol. Histopathol. 39, 659–670
Chai, J. et al. (2021) Antitumor effects of scorpion peptide Smp43 through mitochondrial dysfunction and membrane disruption on hepatocellular carcinoma. J. Nat. Prod. 84, 3147–3160
Muttenthaler, M. et al. (2021) Trends in peptide drug discovery. Nat. Rev: Drug Discov. 20, 309–325
Zheng, B. et al. (2025) Therapeutic peptides: recent advances in discovery, synthesis, and clinical translation. Int. J. Mol. Sci. 26, 5131
Carracedo-Reboredo, P. et al. (2021) A review on machine learning approaches and trends in drug discovery. Comput. Struct. Biotechnol. J. 19, 4538–4558
Goles, M. et al. (2024) Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides. Brief. Bioinform. 25, bbae275
Bian, H. et al. (2024) In silico discovery of stapled peptide inhibitor targeting the Nur77-PPARγ interaction and its anti-breast-cancer efficacy. Adv. Sci. (Weinh.) 11, 2308435
Kim, E-J. et al. (2025) Anticancer activity of snake venom against breast cancer: a scoping review. Toxins 17, 477
Bezerra, P. and Motti, E.F. (2024) 3-NAntC: a potent crotoxin B-derived peptide against the triple-negative MDA-MB-231 breast cancer cell line. Molecules 29, 1646
Stepensky, D. (2018) Pharmacokinetics of toxin-derived peptide drugs. Toxins 10, 483
Li, Q. et al. (2025) Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy. Amino. Acids 57, 25
Wang, Y. et al. (2024) Peptide-mediated nanocarriers for targeted drug delivery: developments and strategies. Pharmaceutics 16, 240
Mahadevappa, R. et al. (2017) Venom peptides: improving specificity in cancer therapy. Trends Cancer 3, 611–614
